A review of erlotinib – an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor

Bibliography

• Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005;353:172-87
   PubMed Web of Science ®Google Scholar
• Medinger M, Drevs J. Receptor tyrosine kinases and anticancer therapy. Curr Pharm Des 2005;11:1139-49
   PubMed Web of Science ®Google Scholar
• Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000;19:6550
   PubMed Web of Science ®Google Scholar
• Hamilton M, Wolf JL, Zborowski D, Tarceva (erlotinib)exposure/effects (EE) analysis from a phase III study in advanced NSCLC: effect of smoking on the PKof erlotinib [abstract 6165]. Proc Am Assoc Cancer Res 2005;46:1451
   Google Scholar
• Ling J, Johnson KA, Miao Z, Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers. Drug Metab Dispos 2006;34:420-6
   PubMed Web of Science ®Google Scholar
• Hamilton M, Wolf JL, Rusk J, Effects of smoking on the pharmacokinetics of erlotinib. Cancer Res 2006;1297:2166-71
   Google Scholar
• Hidalgo M, Siu LL, Nemunaitis J, Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001;19:3267-79
   PubMed Web of Science ®Google Scholar
• Miller AA, Murry DJ, Owzar K, Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J Clin Oncol 2007;25:3055-60
   PubMed Web of Science ®Google Scholar
• Jakacki RI, Hamilton M, Gilbertson RJ, Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. J Clin Oncol 2008;26:4921-7. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Broniscer A, Baker SJ, Stewart CF, Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma. Clin Cancer Res 2009;15:701-7
   PubMed Web of Science ®Google Scholar
• Christiansen SR, Broniscer A, Panetta JC, Pharmacokinetics of erlotinib for the treatment of high-grade glioma in a pediatric patient with cystic fibrosis: case report and review of the literature. Pharmacotherapy 2009;29:858-66
   PubMedGoogle Scholar
• Perez-Soler R. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. Clin Lung Cancer 2006;8(Suppl 1):S7-14
   Google Scholar
• Tarceva® [package insert]. Genentech, Inc. and OSI Pharmaceuticals, Inc.; South San Francisco, CA and Melville, NY, USA
   Google Scholar
• Camp ER, Summy J, Bauer TW, Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor [review]. Clin Cancer Res 2005;11:397-405
   PubMed Web of Science ®Google Scholar
• Pao W, Miller VA, Politi KA, Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73, [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32
   PubMed Web of Science ®Google Scholar
• Moore MJ, Goldstein D, Hamm J, Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-6
   PubMed Web of Science ®Google Scholar
• Johnson JR, Cohen M, Sridhara R, Approval summary for erlotinib for treatment of patients with locally advanced or metastatic nonsmall cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res 2005;11:6414-21
   PubMed Web of Science ®Google Scholar
• Herbst RS, Prager D, Hermann R, TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-9
   PubMed Web of Science ®Google Scholar
• Gatzemeier U, Pluzanska A, Szczesna A, Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007;25:1545-52
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Ciuleanu T, Stelmakh L, SATURN: a double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC [abstract 8001]. J Clin Oncol 2009;27(Suppl):15
   Google Scholar
• Miller VA, O'Connor P, Soh C, A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) [abstract LBA8002]. J Clin Oncol 2009;27(Suppl):18s
   Google Scholar
• Johnson B, Miller V, Amler L, Biomarker evaluation in the randomized, double-blind, placebo controlled, Phase IIIb ATLAS Trial, comparing bevacizumab (B) therapy with or without erlotinib (E), after completion of chemotherapy with B for the treatment of locally advanced, recurrent or metastatic non-small cell lung cancer (NSCLC) [abstract 8LBA]. Eur J Cancer 2009;7(Suppl):5
   Google Scholar
• Tang PA, Gill S, Au HJ, Phase II trial of erlotinib in advanced pancreatic cancer [abstract 4609]. J Clin Oncol 2009;27(Suppl):15
   Google Scholar
• Iyer R, Khushalani N, Tan W, A phase II study of erlotinib in patients (pts) with advanced pancreatic cancer (APC) who are refractory to gemcitabine (G) [abstract 6603]. Eur J Cancer 2009;7(Suppl):391
   Google Scholar
• Boeck S, Vehling-Kaiserb U, Waldschmidtc D, Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’. Anticancer Drugs 2010;21(1):94-100
   PubMedGoogle Scholar
• Dickler MN, Cobleigh MA, Miller KD, Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2009;115:115-21
   PubMed Web of Science ®Google Scholar
• Philip PA, Mahoney MR, Allmer C, Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 2006;24:3069-74
   PubMed Web of Science ®Google Scholar
• Philip PA, Mahoney MR, Allmer C, Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005;23:6657-63
   PubMed Web of Science ®Google Scholar
• Gravis G, Bladou F, Salem N, Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer. Ann Oncol 2008;19:1624-8
   PubMed Web of Science ®Google Scholar
• Eberhard DA, Johnson BE, Amler LC, Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5900-9
   PubMed Web of Science ®Google Scholar
• Zhu CQ, da Cunha Santos G, Ding K, ; for the National Cancer Institute of Canada Clinical Trials Group Study BR.21. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008;26:4268-75
   PubMed Web of Science ®Google Scholar
• Lee J, Jang K, Ki S, Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer 2007;109(8):1561-9
   PubMedGoogle Scholar